Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Ali Z.,,Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects,2013,British Journal of Clinical Pharmacology,64,10.1111/j.1365-2125.2012.04320.x,United Kingdom;United Kingdom,Article,Tadworth;Brentford,0,Journal,2-s2.0-84871151589
Keystone E.,,Erratum: Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine (Annals of the Rheumatic Diseases (2010) 69 (1630-5)),2012,Annals of the Rheumatic Diseases,6,10.1136/ard.2010.143578,,Erratum,,0,Journal,2-s2.0-84868474790
Cavelti-Weder C.,,Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes,2012,Diabetes Care,178,10.2337/dc11-2219,Switzerland,Article,Basel,1,Journal,2-s2.0-84864386088
Sibley C.,,Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes,2012,Arthritis and Rheumatism,120,10.1002/art.34409,United States,Article,Bethesda,1,Journal,2-s2.0-84863228835
Hennig S.,,Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review,2012,Rheumatology International,19,10.1007/s00296-010-1429-y,Austria,Review,Vienna,0,Journal,2-s2.0-84863874705
Stock T.,,"Efficacy and safety of CE-224,535, an antagonist of P2X<inf>7</inf> receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate",2012,Journal of Rheumatology,135,10.3899/jrheum.110874,United States,Article,New York,0,Journal,2-s2.0-84859456520
Gül A.,,Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: An open-label pilot study,2012,Annals of the Rheumatic Diseases,173,10.1136/annrheumdis-2011-155143,Turkey,Article,Istanbul,0,Journal,2-s2.0-84857922054
van Tassell B.,,Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure,2012,PLoS ONE,118,10.1371/journal.pone.0033438,United States,Article,Richmond,1,Journal,2-s2.0-84858405983
Braun-Falco M.,,"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome",2012,Journal of the American Academy of Dermatology,187,10.1016/j.jaad.2010.12.025,Germany,Article,Munich,0,Journal,2-s2.0-84857458569
Ruperto N.,,"A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features",2012,Arthritis and Rheumatism,130,10.1002/art.33342,Italy,Article,Genoa,1,Journal,2-s2.0-84856370186
Balkwill F.R.,,Cancer-related inflammation: Common themes and therapeutic opportunities,2012,Seminars in Cancer Biology,382,10.1016/j.semcancer.2011.12.005,United Kingdom,Review,London,0,Journal,2-s2.0-84857141296
Norheim K.,,"Interleukin-1 inhibition and fatigue in primary sjögren's syndrome - a double blind, randomised clinical trial",2012,PLoS ONE,93,10.1371/journal.pone.0030123,Norway,Article,Stavanger,1,Journal,2-s2.0-84855568775
Alenazi A.,,A retrospective review of autoinflammatory diseases in Saudi children at a rheumatologyclinic,2012,Annals of Saudi Medicine,6,10.5144/0256-4947.2012.43,Saudi Arabia,Review,Riyadh,1,Journal,2-s2.0-84864569149
Shendi H.,,Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome,2012,Rheumatology International,20,10.1007/s00296-009-1322-8,United Kingdom,Article,Belfast,0,Journal,2-s2.0-84857115753
Stankovic Stojanovic K.,,Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure.,2012,"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association",74,10.1093/ndt/gfr528,France,Article,Paris,1,Journal,2-s2.0-84871914109
Rissanen A.,,"Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: Results of a randomized, placebo-controlled trial",2012,"Diabetes, Obesity and Metabolism",92,10.1111/j.1463-1326.2012.01637.x,Finland;Finland,Article,Helsinki;Helsinki,0,Journal,2-s2.0-84873271227
Berda-Haddad Y.,,Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1α,2011,Proceedings of the National Academy of Sciences of the United States of America,132,10.1073/pnas.1116848108,France;France,Article,Marseille;Marseille,1,Journal,2-s2.0-84855504820
Koné-Paut I.,,Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: Results of a double-blind placebo-controlled randomized withdrawal study,2011,Arthritis Research and Therapy,85,10.1186/ar3535,France,Article,Le Kremlin-Bicetre,1,Journal,2-s2.0-84855796483
Kuemmerle-Deschner J.,,NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment,2011,Arthritis Research and Therapy,40,10.1186/ar3526,Germany,Article,Tubingen,1,Journal,2-s2.0-82655170808
Bodar E.,,On-demand anakinra treatment is effective in mevalonate kinase deficiency,2011,Annals of the Rheumatic Diseases,99,10.1136/ard.2011.149922,Netherlands,Article,Nijmegen,0,Journal,2-s2.0-84860389029
Kuemmerle-Deschner J.B.,,"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes",2011,Annals of the Rheumatic Diseases,143,10.1136/ard.2011.152728,Germany,Article,Tubingen,0,Journal,2-s2.0-84860389457
Mueller S.,,Muckle-wells syndrome effectively treated with canakinumab: Is the recommended dosing schedule mandatory?,2011,Dermatology,9,10.1159/000331580,Switzerland,Review,Basel,0,Journal,2-s2.0-82455212471
Sumpter K.,,Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes,2011,Pediatric Diabetes,63,10.1111/j.1399-5448.2011.00761.x,United States,Article,Dallas,0,Journal,2-s2.0-80055084799
Rider P.,,IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation,2011,Journal of Immunology,279,10.4049/jimmunol.1102048,Israel,Article,Beer Sheba,1,Journal,2-s2.0-80555133279
Scott I.C.,,A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis,2011,Journal of Cardiology Cases,22,10.1016/j.jccase.2011.07.003,United Kingdom,Article,London,1,Journal,2-s2.0-81155159706
Vezzani A.,,Therapeutic potential of new antiinflammatory drugs,2011,Epilepsia,32,10.1111/j.1528-1167.2011.03242.x,Italy,Conference Paper,Milan,1,Journal,2-s2.0-80053580204
Cavelti-Weder C.,,Inhibition of IL-1β improves fatigue in type 2 diabetes,2011,Diabetes Care,37,10.2337/dc11-1196,Switzerland,Letter,Basel,1,Journal,2-s2.0-84860805156
Meinzer U.,,Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature,2011,Seminars in Arthritis and Rheumatism,149,10.1016/j.semarthrit.2010.11.003,France,Article,Le Kremlin-Bicetre,0,Journal,2-s2.0-79955138270
Vezzani A.,,"IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures",2011,"Brain, Behavior, and Immunity",225,10.1016/j.bbi.2011.03.018,Italy,Review,Milan,0,Journal,2-s2.0-79955681780
Ridker P.M.,,Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS),2011,American Heart Journal,590,10.1016/j.ahj.2011.06.012,United States,Article,Boston,0,Journal,2-s2.0-80053644777
Szturz P.,,Schnitzler syndrome: Diagnostics and treatment,2011,Klinicka Onkologie,9,,Czech Republic,Review,Brno,0,Journal,2-s2.0-80052199830
Alten R.,,"Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study",2011,BMC Musculoskeletal Disorders,85,10.1186/1471-2474-12-153,Germany,Article,Berlin,1,Journal,2-s2.0-80052189130
Stoffels M.,,Hyper-IgD syndrome or mevalonate kinase deficiency,2011,Current Opinion in Rheumatology,37,10.1097/BOR.0b013e328349c3b1,Netherlands,Review,Nijmegen,0,Journal,2-s2.0-80052023093
Chevalier X.,,Desperately looking for the right target in osteoarthritis: The anti-IL-1 strategy,2011,Arthritis Research and Therapy,26,10.1186/ar3436,France,Review,Creteil,1,Journal,2-s2.0-80052209352
Ahmadi N.,,Cryopyrin-associated periodic syndromes: Otolaryngologic and audiologic manifestations,2011,Otolaryngology - Head and Neck Surgery,40,10.1177/0194599811402296,United States,Article,"Washington, D.C.",0,Journal,2-s2.0-84855939469
Cohen S.,,"A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee",2011,Arthritis Research and Therapy,105,10.1186/ar3430,United States,Article,Dallas,1,Journal,2-s2.0-79960862976
Mitroulis I.,,The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis,2011,Annals of the Rheumatic Diseases,42,10.1136/ard.2010.146878,Greece,Letter,Komotini,0,Journal,2-s2.0-79957663056
Van Asseldonk E.,,"Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: A randomized, double-blind, placebo-controlled study",2011,Journal of Clinical Endocrinology and Metabolism,108,10.1210/jc.2010-2992,Netherlands,Article,Nijmegen,1,Journal,2-s2.0-79960086288
Schlesinger N.,,"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study",2011,Annals of the Rheumatic Diseases,149,10.1136/ard.2010.144063,United States,Article,New Brunswick,1,Journal,2-s2.0-79957646006
Furuta T.,,Association of interleukin-1 gene polymorphisms with sudden sensorineural hearing loss and Ménière's disease,2011,International Journal of Immunogenetics,33,10.1111/j.1744-313X.2011.01004.x,Japan;Japan,Article,Nagoya;Aichi Prefecture,0,Journal,2-s2.0-79956265355
Vojinovic J.,,Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis,2011,Arthritis and Rheumatism,143,10.1002/art.30238,Serbia,Article,,1,Journal,2-s2.0-79955552937
Quartier P.,,"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)",2011,Annals of the Rheumatic Diseases,316,10.1136/ard.2010.134254,France,Article,Paris,1,Journal,2-s2.0-79953323633
Stojanov S.,,"Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade",2011,Proceedings of the National Academy of Sciences of the United States of America,159,10.1073/pnas.1103681108,United States;Germany,Article,Bethesda;Munich,1,Journal,2-s2.0-79955147587
Dinarello C.,,Interleukin-1 in the pathogenesis and treatment of inflammatory diseases,2011,Blood,1129,10.1182/blood-2010-07-273417,United States;Netherlands,Article,Denver;Nijmegen,0,Journal,2-s2.0-79953813107
Goldbach-Mansky R.,,Current status of understanding the pathogenesis and management of patients with NOMID/CINCA,2011,Current Rheumatology Reports,90,10.1007/s11926-011-0165-y,United States,Article,Bethesda,0,Journal,2-s2.0-79957456776
Schlesinger N.,,"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: Results of a randomized, dose-ranging study",2011,Arthritis Research and Therapy,86,10.1186/ar3297,United States,Article,New Brunswick,1,Journal,2-s2.0-79953094557
Bulua A.,,Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS),2011,Journal of Experimental Medicine,503,10.1084/jem.20102049,United States;United States,Article,New York;Bethesda,1,Journal,2-s2.0-79952184583
Funck-Brentano T.,,First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine,2011,Rheumatology,18,10.1093/rheumatology/keq358,France,Letter,Paris,1,Journal,2-s2.0-79952011681
Chiu H.,,Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan,2011,British Journal of Dermatology,47,10.1111/j.1365-2133.2010.10137.x,Taiwan,Article,Taipei,0,Journal,2-s2.0-79952380166
Hung A.,,IL-1β Receptor antagonist reduces inflammation in hemodialysis patients,2011,Journal of the American Society of Nephrology,67,10.1681/ASN.2010070760,United States;United States,Article,Nashville;,1,Journal,2-s2.0-79952336504
Özen S.,,Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine,2011,Journal of Rheumatology,94,10.3899/jrheum.100718,Turkey,Article,Ankara,0,Journal,2-s2.0-79952425658
Kuemmerle-Deschner J.,,Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome,2011,Arthritis and Rheumatism,108,10.1002/art.30149,Germany,Article,Tubingen,1,Journal,2-s2.0-79953677480
Kuemmerle-Deschner J.B.,,"Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)",2011,Arthritis Research and Therapy,78,10.1186/ar3266,Germany,Article,Tubingen,1,Journal,2-s2.0-79952053673
van de Veerdonk F.,,Anakinra for the inflammatory complications of chronic granulomatous disease,2011,Netherlands Journal of Medicine,17,,Netherlands;Netherlands,Editorial,Nijmegen;Nijmegen,0,Journal,2-s2.0-79952947988
Pathak S.,,IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease,2011,Journal of Immunology,46,10.4049/jimmunol.1002275,United States,Article,Hempstead,1,Journal,2-s2.0-79251570253
Galea J.,,Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: Results of a dose-ranging study,2011,Journal of Cerebral Blood Flow and Metabolism,61,10.1038/jcbfm.2010.103,United Kingdom;United Kingdom,Article,Salford;Manchester,1,Journal,2-s2.0-79551687466
Vandanmagsar B.,,The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance,2011,Nature Medicine,1341,10.1038/nm.2279,United States;United States,Article,Baton Rouge;Baton Rouge,0,Journal,2-s2.0-79751512463
Donath M.,,Type 2 diabetes as an inflammatory disease,2011,Nature Reviews Immunology,1834,10.1038/nri2925,Switzerland,Review,Basel,0,Journal,2-s2.0-79151478555
Korppi M.,,Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report,2011,"Acta Paediatrica, International Journal of Paediatrics",33,10.1111/j.1651-2227.2010.01974.x,Finland,Review,Tampere,0,Journal,2-s2.0-78650092436
De Koning H.,,Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome,2011,Journal of Allergy and Clinical Immunology,40,10.1016/j.jaci.2011.05.023,Netherlands;Netherlands;Netherlands,Article,Nijmegen;Nijmegen;Nijmegen,0,Journal,2-s2.0-82555192469
Bruck N.,,Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids,2011,Journal of Clinical Rheumatology,100,10.1097/RHU.0b013e318205092d,Germany,Article,Dresden,0,Journal,2-s2.0-78651365935
Kapoor M.,,Role of proinflammatory cytokines in the pathophysiology of osteoarthritis,2011,Nature Reviews Rheumatology,1123,10.1038/nrrheum.2010.196,Canada,Review,Montreal,0,Journal,2-s2.0-78650983649
Cantarini L.,,Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment,2010,Clinical and Experimental Rheumatology,50,,Italy,Letter,Siena,0,Journal,2-s2.0-78650552920
Aït-Abdesselam T.,,Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome,2010,Joint Bone Spine,8,10.1016/j.jbspin.2010.04.018,France,Letter,Rouen,0,Journal,2-s2.0-78649907431
Swart J.F.,,The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis,2010,Expert Opinion on Biological Therapy,34,10.1517/14712598.2010.532785,Netherlands;Netherlands;Netherlands,Review,Utrecht;Amsterdam;Amsterdam,0,Journal,2-s2.0-78249256670
Stienstra R.,,The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity,2010,Cell Metabolism,407,10.1016/j.cmet.2010.11.011,Netherlands,Article,Nijmegen,1,Journal,2-s2.0-78649498271
Hsiao J.,,Hidradenitis suppurativa and concomitant pyoderma gangrenosum: A case series and literature review,2010,Archives of Dermatology,78,10.1001/archdermatol.2010.328,United States,Article,San Francisco,1,Journal,2-s2.0-78349251342
Joosten L.,,Engagement of fatty acids with toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis,2010,Arthritis and Rheumatism,174,10.1002/art.27667,Netherlands,Article,Nijmegen,0,Journal,2-s2.0-78249286865
Solovic I.,,"Series ""update on tuberculosis"" edited by C. Lange, M. Raviglione, W.W. Yew and G.B. Migliori number 2 in this series: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement",2010,European Respiratory Journal,334,10.1183/09031936.00028510,Slovakia,Review,,1,Journal,2-s2.0-78349243317
Masters S.,,Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β 2 in type 2 diabetes,2010,Nature Immunology,778,10.1038/ni.1935,Ireland,Article,Dublin,0,Journal,2-s2.0-77956958947
Bernatsky S.,,Demyelinating events in rheumatoid arthritis after drug exposures,2010,Annals of the Rheumatic Diseases,57,10.1136/ard.2009.111500,Canada;Canada,Article,Montreal;Montreal,0,Journal,2-s2.0-77956021184
Klein A.,,Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with Anakinra,2010,Klinische Padiatrie,14,10.1055/s-0029-1239527,Germany,Article,Sankt Augustin,0,Journal,2-s2.0-77951627028
Van Der Meer J.,,Blocking IL-1β to slow down progression of ALS?,2010,Proceedings of the National Academy of Sciences of the United States of America,7,10.1073/pnas.1007946107,Netherlands,Note,Nijmegen,1,Journal,2-s2.0-77955630849
Meissner F.,,Mutant superoxide dismutase 1-induced IL-1β accelerates ALS pathogenesis,2010,Proceedings of the National Academy of Sciences of the United States of America,179,10.1073/pnas.1002396107,Germany,Article,Berlin,1,Journal,2-s2.0-77955649302
Dinarello C.,,Why not treat human cancer with interleukin-1 blockade?,2010,Cancer and Metastasis Reviews,194,10.1007/s10555-010-9229-0,United States;Netherlands,Review,Denver;Nijmegen,1,Journal,2-s2.0-77954551165
Simon A.,,Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome,2010,Proceedings of the National Academy of Sciences of the United States of America,127,10.1073/pnas.0914118107,United States;Netherlands,Article,Bethesda;Nijmegen,1,Journal,2-s2.0-77953089570
Abbate A.,,Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study),2010,American Journal of Cardiology,238,10.1016/j.amjcard.2009.12.059,United States,Article,Richmond,0,Journal,2-s2.0-77951665667
Duewell P.,,NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals,2010,Nature,1918,10.1038/nature08938,Germany;United States,Article,Munich;Worcester,0,Journal,2-s2.0-77951800951
Durand M.,,Macrophage activation syndrome treated with anakinra,2010,Journal of Rheumatology,48,10.3899/jrheum.091046,Canada,Letter,Montreal,1,Journal,2-s2.0-77950687131
Abbate A.,,Interleukin-1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse,2010,European Journal of Heart Failure,76,10.1093/eurjhf/hfq017,United States;United States,Article,Richmond;Richmond,1,Journal,2-s2.0-77950279969
Colina M.,,Dysregulation of P2X<inf>7</inf> receptor-inflammasome axis in SAPHO syndrome: Successful treatment with anakinra,2010,Rheumatology,62,10.1093/rheumatology/keq074,Italy,Letter,Ferrara,1,Journal,2-s2.0-77954222687
Miyamae T.,,Effect of anakinra on arthropathy in CINCA/NOMID syndrome,2010,Pediatric Rheumatology,21,10.1186/1546-0096-8-9,Japan,Article,Yokohama,1,Journal,2-s2.0-77951159682
Mandrup-Poulsen T.,,Blockade of interleukin 1 in type 1 diabetes mellitus,2010,Nature Reviews Endocrinology,166,10.1038/nrendo.2009.271,Denmark,Review,Gentofte,0,Journal,2-s2.0-77649108168
Kastner D.,,Autoinflammatory Disease Reloaded: A Clinical Perspective,2010,Cell,309,10.1016/j.cell.2010.03.002,United States,Short Survey,Bethesda,1,Journal,2-s2.0-77950363011
Dinarello C.A.,,Anti-inflammatory Agents: Present and Future,2010,Cell,516,10.1016/j.cell.2010.02.043,United States;Netherlands,Review,Denver;Nijmegen,1,Journal,2-s2.0-77950355734
Cohen I.,,Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation,2010,Proceedings of the National Academy of Sciences of the United States of America,223,10.1073/pnas.0915018107,Israel,Article,Beer Sheba,1,Journal,2-s2.0-77249085646
Naumann L.,,IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease,2010,Annals of the Rheumatic Diseases,67,10.1136/ard.2009.108068,Germany,Letter,Berlin,0,Journal,2-s2.0-75749100258
Bilginer Y.,,Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease,2010,Clinical Rheumatology,77,10.1007/s10067-009-1279-8,Turkey,Article,Ankara,0,Journal,2-s2.0-77949884645
Aronson I.K.,,Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: An overview,2010,Dermatologic Therapy,25,10.1111/j.1529-8019.2010.01339.x,United States,Review,Chicago,0,Journal,2-s2.0-77955028074
Kitley J.L.,,Neurologic manifestations of the cryopyrin-associated periodic syndrome,2010,Neurology,50,10.1212/WNL.0b013e3181d9ed69,United Kingdom,Article,Southampton,0,Journal,2-s2.0-77951473388
Lepore L.,,Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra,2010,Journal of Pediatrics,81,10.1016/j.jpeds.2010.02.040,Italy,Article,Trieste,0,Journal,2-s2.0-77955291693
Neven B.,,"Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome",2010,Arthritis and Rheumatism,175,10.1002/art.25057,France;France,Article,Paris;Paris,0,Journal,2-s2.0-74849115591
So A.,,"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study",2010,Arthritis and Rheumatism,199,10.1002/art.27600,Switzerland,Article,Lausanne,0,Journal,2-s2.0-77957688721
Beyer C.,,The role of microparticles in the pathogenesis of rheumatic diseases,2010,Nature Reviews Rheumatology,186,10.1038/nrrheum.2009.229,Germany,Review,Erlangen,0,Journal,2-s2.0-75149125508
Terkeltaub R.,,Update on gout: New therapeutic strategies and options,2010,Nature Reviews Rheumatology,228,10.1038/nrrheum.2009.236,United States,Review,San Diego,0,Journal,2-s2.0-75149194057
Libby P.,,Inflammation in Atherosclerosis. From Pathophysiology to Practice,2009,Journal of the American College of Cardiology,1254,10.1016/j.jacc.2009.09.009,United States,Review,Boston,1,Journal,2-s2.0-70450189795
Bodar E.,,Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra),2009,Netherlands Journal of Medicine,26,,Netherlands,Article,Nijmegen,0,Journal,2-s2.0-70350461271
Lehtimäki K.,,Levels of IL-1β and IL-1ra in cerebrospinal fluid of human patients after single and prolonged seizures,2009,NeuroImmunoModulation,26,10.1159/000243081,Finland,Article,Tampere,0,Journal,2-s2.0-70349836252
Singh D.,,IL-1 inhibition with anakinra in a patient with refractory gout,2009,Journal of Clinical Rheumatology,29,10.1097/RHU.0b013e3181be2423,United States,Article,Kansas City,0,Journal,2-s2.0-70350168010
Carmi Y.,,The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis,2009,Journal of Immunology,139,10.4049/jimmunol.0901511,Israel,Article,Beer Sheba,1,Journal,2-s2.0-70449732756
Terkeltaub R.,,"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study",2009,Annals of the Rheumatic Diseases,220,10.1136/ard.2009.108936,United States;United States,Article,San Diego;,1,Journal,2-s2.0-70349402166
Gratton S.,,Case of anakinra as a steroid-sparing agent for gout inflammation,2009,Arthritis Care and Research,38,10.1002/art.24694,United States;United States,Article,San Francisco;San Francisco,1,Journal,2-s2.0-69749116766
Chae J.,,Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy,2009,British Journal of Haematology,152,10.1111/j.1365-2141.2009.07733.x,United States,Review,Bethesda,1,Journal,2-s2.0-69049085064
Larsen C.,,Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes,2009,Diabetes Care,273,10.2337/dc09-0533,Denmark,Article,Gentofte,1,Journal,2-s2.0-69549105888
Wanderer A.,,Rationale for IL-1β targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease,2009,Journal of Pediatric Hematology/Oncology,10,10.1097/MPH.0b013e3181acd89d,United States,Note,Denver,0,Journal,2-s2.0-68849108112
Masters S.,,Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease,2009,Annual Review of Immunology,735,10.1146/annurev.immunol.25.022106.141627,United States,Review,Bethesda,0,Book Series,2-s2.0-67650736238
Martinon F.,,The inflammasomes: Guardians of the body,2009,Annual Review of Immunology,1589,10.1146/annurev.immunol.021908.132715,United States,Review,Boston,0,Book Series,2-s2.0-66749174867
Announ N.,,Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure,2009,Joint Bone Spine,52,10.1016/j.jbspin.2009.01.001,Switzerland,Article,Geneva,0,Journal,2-s2.0-67649798632
Reddy S.,,An autoinflammatory disease due to homozygous deletion of the IL1RN locus,2009,New England Journal of Medicine,275,10.1056/NEJMoa0809568,United States,Article,Wauwatosa,0,Journal,2-s2.0-66649113371
Lachmann H.J.,,Use of canakinumab in the cryopyrin-associated periodic syndrome,2009,New England Journal of Medicine,582,10.1056/NEJMoa0810787,United Kingdom,Article,London,0,Journal,2-s2.0-66649102432
Aksentijevich I.,,An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist,2009,New England Journal of Medicine,619,10.1056/NEJMoa0807865,United States,Article,Bethesda,0,Journal,2-s2.0-66649121678
Olson J.,,Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model,2009,Ocular Immunology and Inflammation,20,10.1080/09273940802710705,United States,Article,Denver,0,Journal,2-s2.0-68849093907
Bacconnier L.,,Erosive osteoarthritis of the hand: Clinical experience with anakinra,2009,Annals of the Rheumatic Diseases,61,10.1136/ard.2008.094284,France,Letter,Montpellier,0,Journal,2-s2.0-67449124615
Mertens M.,,Anakinra for rheumatoid arthritis: A systematic review,2009,Journal of Rheumatology,183,10.3899/jrheum.090074,United States,Article,Minneapolis,0,Journal,2-s2.0-67149130597
Lachmann H.J.,,In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes,2009,Journal of Experimental Medicine,216,10.1084/jem.20082481,United Kingdom,Article,London,0,Journal,2-s2.0-66049094734
Ferrara J.,,Graft-versus-host disease,2009,The Lancet,1378,10.1016/S0140-6736(09)60237-3,United States,Review,Ann Arbor,0,Journal,2-s2.0-65349171937
Vambutas A.,,Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED,2009,PLoS ONE,44,10.1371/journal.pone.0005293,United States;United States,Article,Great Neck;Manhasset,1,Journal,2-s2.0-65549129527
Chevalier X.,,"Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study",2009,Arthritis Care and Research,268,10.1002/art.24096,France;France,Article,Creteil;Creteil,0,Journal,2-s2.0-62549104691
Nedjai B.,,Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome,2009,Arthritis and Rheumatism,84,10.1002/art.24294,United Kingdom,Article,London,1,Journal,2-s2.0-59649101629
Moser C.,,Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation,2009,Nephrology Dialysis Transplantation,91,10.1093/ndt/gfn646,Austria,Article,Vienna,1,Journal,2-s2.0-58449114163
Picco P.,,Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): An unrecognized autoinflammatory disease?,2009,Arthritis and Rheumatism,103,10.1002/art.24174,Italy;Italy,Article,Genoa;Genoa,1,Journal,2-s2.0-58249112751
Lust J.,,Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component,2009,Mayo Clinic Proceedings,175,10.4065/84.2.114,United States,Article,Rochester,0,Journal,2-s2.0-61449122079
Ohlsson V.,,Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA),2008,Rheumatology,46,10.1093/rheumatology/ken030,United Kingdom,Letter,Bristol,1,Journal,2-s2.0-43049158200
Van Der Hilst J.,,"Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome",2008,Medicine,237,10.1097/MD.0b013e318190cfb7,Netherlands;Netherlands,Article,Nijmegen;Nijmegen,0,Journal,2-s2.0-58149195381
Zhang K.,,Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms,2008,Arthritis and Rheumatism,111,10.1002/art.23734,United States,Article,Cincinnati,0,Journal,2-s2.0-49749127387
Hoffman H.,,Efficacy and safety of rilonacept (Interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies,2008,Arthritis and Rheumatism,416,10.1002/art.23687,United States,Article,San Diego,1,Journal,2-s2.0-49449094179
Rusai K.,,Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury,2008,Transplant International,39,10.1111/j.1432-2277.2008.00651.x,Germany;Hungary,Article,Munich;Budapest,1,Journal,2-s2.0-42949169489
Calligaris L.,,The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever,2008,European Journal of Pediatrics,95,10.1007/s00431-007-0547-3,Italy;Italy,Article,Trieste;Trieste,1,Journal,2-s2.0-41849105723
Ikonomidis I.,,Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis,2008,Circulation,190,10.1161/CIRCULATIONAHA.107.731877,,Article,,1,Journal,2-s2.0-47649086507
Abbate A.,,"Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction",2008,Circulation,234,10.1161/CIRCULATIONAHA.107.740233,United States,Article,Richmond,1,Journal,2-s2.0-47649105757
Gattorno M.,,Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome,2008,Arthritis and Rheumatism,213,10.1002/art.23475,Italy;Italy,Article,Genoa;Genoa,1,Journal,2-s2.0-43949128071
Gattorno M.,,The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis,2008,Arthritis and Rheumatism,270,10.1002/art.23437,Italy;Italy,Article,Genoa;Genoa,1,Journal,2-s2.0-43949116263
Lequerré T.,,Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: Preliminary experience in France,2008,Annals of the Rheumatic Diseases,301,10.1136/ard.2007.076034,France,Article,Rouen,1,Journal,2-s2.0-39549109506
Spulber S.,,Blunted neurogenesis and gliosis due to transgenic overexpression of human soluble IL-1ra in the mouse,2008,European Journal of Neuroscience,42,10.1111/j.1460-9568.2008.06050.x,Sweden,Article,Stockholm,0,Journal,2-s2.0-39049146540
Sacré K.,,Dramatic improvement following interleukin 1β blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-α therapy,2008,Journal of Rheumatology,62,,Turkey,Letter,Bolu,0,Journal,2-s2.0-39549122472
McGonagle D.,,Successful treatment of resistant pseudogout with anakinra,2008,Arthritis and Rheumatism,91,10.1002/art.23119,United Kingdom;United Kingdom,Article,Halifax;Leeds,1,Journal,2-s2.0-39749175570
Ryan J.,,IL-1 blockade in Schnitzler syndrome: Ex vivo findings correlate with clinical remission,2008,Journal of Allergy and Clinical Immunology,71,10.1016/j.jaci.2007.09.021,United States,Letter,Bethesda,0,Journal,2-s2.0-38149024742
Botsios C.,,"Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis",2007,Reumatismo,20,,Italy,Article,Padua,0,Journal,2-s2.0-34447272928
Kötter I.,,Anakinra in Patients with Treatment-Resistant Adult-Onset Still's Disease: Four Case Reports with Serial Cytokine Measurements and a Review of the Literature,2007,Seminars in Arthritis and Rheumatism,107,10.1016/j.semarthrit.2007.04.002,Germany,Article,Tubingen,0,Journal,2-s2.0-34547878809
McGonagle D.,,Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra [1],2007,Annals of the Rheumatic Diseases,112,10.1136/ard.2007.073759,United Kingdom;United Kingdom,Letter,Halifax;Leeds,0,Journal,2-s2.0-34548667797
de Koning H.,,Comment on: Schnitzlers syndrome-exacerbation after anti-TNF treatment [5],2007,Rheumatology,6,10.1093/rheumatology/kem244,Netherlands,Letter,Nijmegen,1,Journal,2-s2.0-35548940313
Kamari Y.,,Differential role and tissue specificity of interleukin-1α gene expression in atherogenesis and lipid metabolism,2007,Atherosclerosis,82,10.1016/j.atherosclerosis.2006.11.026,Israel,Article,Ramal Aviv,0,Journal,2-s2.0-35248883867
Gattorno M.,,Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations,2007,Arthritis and Rheumatism,188,10.1002/art.22842,Italy;Italy,Article,Genoa;Genoa,1,Journal,2-s2.0-34848875155
Settas L.,,Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra),2007,Journal of Clinical Rheumatology,36,10.1097/RHU.0b013e31812e00a1,Greece,Article,Thessaloniki,0,Journal,2-s2.0-34548413549
Chen C.J.,,Identification of a key pathway required for the sterile inflammatory response triggered by dying cells,2007,Nature Medicine,613,10.1038/nm1603,Taiwan;United States,Article,Taipei;Worcester,0,Journal,2-s2.0-34447116244
Kalliolias G.D.,,"Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: Experience from an uncontrolled trial [6]",2007,Annals of the Rheumatic Diseases,72,10.1136/ard.2006.066381,Greece,Letter,Patra,0,Journal,2-s2.0-34249799278
Larsen C.,,Interleukin-1-receptor antagonist in type 2 diabetes mellitus,2007,New England Journal of Medicine,1231,10.1056/NEJMoa065213,Denmark,Article,Gentofte,0,Journal,2-s2.0-34247170807
So A.,,A pilot study of IL-1 inhibition by anakinra in acute gout,2007,Arthritis Research and Therapy,557,10.1186/ar2143,Switzerland,Article,Lausanne,1,Journal,2-s2.0-34047174085
Thornton B.D.,,Successful Treatment of Renal Amyloidosis Due to Familial Cold Autoinflammatory Syndrome Using an Interleukin 1 Receptor Antagonist,2007,American Journal of Kidney Diseases,37,10.1053/j.ajkd.2006.10.026,United States,Article,Sacramento,0,Journal,2-s2.0-33847364065
Bartfai T.,,"Interleukin-1 system in CNS stress: Seizures, fever, and neurotrauma",2007,Annals of the New York Academy of Sciences,91,10.1196/annals.1391.022,United States,Conference Paper,San Diego,0,Book Series,2-s2.0-35548985825
Behrens E.M.,,Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis,2006,Journal of Rheumatology,46,,United States,Article,Philadelphia,0,Journal,2-s2.0-33749994238
Goldbach-Mansky R.,,Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition,2006,New England Journal of Medicine,656,10.1056/NEJMoa055137,United States,Article,Bethesda,0,Journal,2-s2.0-33746876396
Fleischmann R.,,Safety of extended treatment with anakinra in patients with rheumatoid arthritis,2006,Annals of the Rheumatic Diseases,189,10.1136/ard.2005.048371,United States,Article,Dallas,0,Journal,2-s2.0-33746578466
Chae J.,,"The B30.2 domain of pyrin, the familial mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production",2006,Proceedings of the National Academy of Sciences of the United States of America,400,10.1073/pnas.0602081103,United States;United States,Article,Bethesda;Bethesda,1,Journal,2-s2.0-33745631232
Lachmann H.J.,,Systemic amyloidosis,2006,Current Opinion in Pharmacology,58,10.1016/j.coph.2005.10.005,United Kingdom,Review,London,0,Journal,2-s2.0-33644835426
Rynne M.,,Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism,2006,Annals of the Rheumatic Diseases,63,10.1136/ard.2005.038091,United Kingdom,Article,Leeds,0,Journal,2-s2.0-33645125321
De Koning H.,,Beneficial response to anakinra and thalidomide in Schnitzler's syndrome,2006,Annals of the Rheumatic Diseases,124,10.1136/ard.2005.045245,Netherlands,Article,Nijmegen,0,Journal,2-s2.0-33645119818
Gosavi S.,,Topological frustration and the folding of interleukin-1β,2006,Journal of Molecular Biology,106,10.1016/j.jmb.2005.11.074,United States,Article,San Diego,0,Journal,2-s2.0-33645030244
Xiong Y.,,Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1,2006,Journal of Interferon and Cytokine Research,27,10.1089/jir.2006.26.83,United States,Article,Rochester,0,Journal,2-s2.0-33644844811
Cailliez M.,,Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.,2006,Journal of inherited metabolic disease,90,10.1007/s10545-006-0408-7,France,Article,Marseille,0,Journal,2-s2.0-33845807104
Kondera-Anasz Z.,,"Concentrations of interleukin (IL)-1α, IL-1 soluble receptor type II (IL-1 sRII) and IL-1 receptor antagonist (IL-1 Ra) in the peritoneal fluid and serum of infertile women with endometriosis",2005,European Journal of Obstetrics and Gynecology and Reproductive Biology,45,10.1016/j.ejogrb.2005.04.019,Poland,Article,Katowice,0,Journal,2-s2.0-28444443752
Mazodier K.,,Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome,2005,Blood,178,10.1182/blood-2005-05-1980,,Article,,0,Journal,2-s2.0-27744607629
Emsley H.C.A.,,A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients,2005,"Journal of Neurology, Neurosurgery and Psychiatry",306,10.1136/jnnp.2004.054882,United Kingdom,Article,Liverpool,1,Journal,2-s2.0-25444517949
Martinez-Taboada V.,,Successful treatment of refractory Schnitzler syndrome with anakinra: Comment on the article by Hawkins et al [1],2005,Arthritis and Rheumatism,76,10.1002/art.21101,Spain,Letter,Santander,1,Journal,2-s2.0-22244467732
Bodar E.,,Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: Introducing a vaccination provocation model,2005,Netherlands Journal of Medicine,140,,Netherlands,Article,Nijmegen,0,Journal,2-s2.0-23844552119
Chevalier X.,,Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: A multicenter study,2005,Journal of Rheumatology,146,,France,Article,Creteil,0,Journal,2-s2.0-22244474585
Fitzgerald A.,,Rapid responses to anakinra in patients with refractory adult-onset Still's disease,2005,Arthritis and Rheumatism,279,10.1002/art.21061,Canada,Article,Calgary,0,Journal,2-s2.0-18644370644
Pascual V.,,Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade,2005,Journal of Experimental Medicine,660,10.1084/jem.20050473,United States;United States,Article,Dallas;Dallas,1,Journal,2-s2.0-18644385243
Hoffman H.M.,,Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist,2004,Lancet,435,10.1016/S0140-6736(04)17401-1,United States,Article,San Diego,0,Journal,2-s2.0-8444225132
Simon A.,,Beneficial response to interleukin 1 receptor antagonist in traps [2],2004,American Journal of Medicine,138,10.1016/j.amjmed.2004.02.039,Netherlands,Letter,Nijmegen,0,Journal,2-s2.0-3843110981
Bresnihan B.,,"Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-Week randomized, placebo-controlled trial",2004,Journal of Rheumatology,67,,Ireland,Article,Dublin,0,Journal,2-s2.0-2642550601
Agostini L.,,NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder,2004,Immunity,1168,10.1016/S1074-7613(04)00046-9,Switzerland,Article,Lausanne,1,Journal,2-s2.0-1642285783
Joosten L.A.B.,,Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction,2004,American Journal of Pathology,61,10.1016/S0002-9440(10)63357-3,Netherlands,Article,Nijmegen,0,Journal,2-s2.0-4344717421
Bresnihan B.,,Clinical and radiological effects of anakinra in patients with rheumatoid arthritis,2003,Rheumatology,61,,Ireland,Article,Dublin,0,Journal,2-s2.0-4444360736
Fleischmann R.,,"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial",2003,Arthritis and Rheumatism,306,10.1002/art.10870,United States,Article,Dallas,0,Journal,2-s2.0-0037389680
Maedler K.,,Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets,2002,Journal of Clinical Investigation,908,10.1172/JCI200215318,Switzerland,Article,Zurich,1,Journal,2-s2.0-0036738398
De Jong B.A.,,Production of IL-1β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis,2002,Journal of Neuroimmunology,90,10.1016/S0165-5728(02)00056-5,Netherlands,Article,Leiden,0,Journal,2-s2.0-0035999548
Calkins C.,,IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia,2002,Journal of Endotoxin Research,73,10.1177/09680519020080010601,United States,Article,Denver,1,Journal,2-s2.0-0036123008
Hoffman H.M.,,Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome,2001,Nature Genetics,1119,10.1038/ng756,United States,Article,San Diego,0,Journal,2-s2.0-0035179970
Mohan N.,,Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides,2001,Arthritis and Rheumatism,707,10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W,United States,Article,"Washington, D.C.",0,Journal,2-s2.0-0035674613
Mansfield E.,,"The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments",2001,Blood,150,10.1182/blood.V98.3.851,United States;United States,Article,Bethesda;Bethesda,0,Journal,2-s2.0-0035437141
Boutin H.,,Role of IL-1α and IL-1β in ischemic brain damage,2001,Journal of Neuroscience,399,10.1523/jneurosci.21-15-05528.2001,United Kingdom,Article,Manchester,1,Journal,2-s2.0-0035413361
Cunnane G.,,The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis,2001,Rheumatology,100,10.1093/rheumatology/40.1.62,Ireland,Article,Dublin,1,Journal,2-s2.0-0035144287
Jiang Y.,,"A multicenter, double-blind, dose-ranging, randomized, placebo- controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores",2000,Arthritis and Rheumatism,384,10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P,,Article,,1,Journal,2-s2.0-0034083128
McDermott M.F.,,"Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes",1999,Cell,970,10.1016/S0092-8674(00)80721-7,United Kingdom,Article,London,1,Journal,2-s2.0-0033515520
Lust J.,,The role of interleukin-1β in the pathogenesis of multiple myeloma,1999,Hematology/Oncology Clinics of North America,70,10.1016/S0889-8588(05)70115-5,United States;United States,Article,Rochester;Rochester,0,Journal,2-s2.0-0033401640
Bresnihan B.,,Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist,1998,Arthritis and Rheumatism,881,10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2,Ireland,Article,Dublin,1,Journal,2-s2.0-17444394445
Takebe N.,,Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients,1998,Journal of Interferon and Cytokine Research,8,10.1089/jir.1998.18.321,United States,Article,New York,0,Journal,2-s2.0-0031969063
Opal S.M.,,"Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial",1997,Critical Care Medicine,603,10.1097/00003246-199707000-00010,United States;United States,Review,Providence;Providence,0,Journal,2-s2.0-0030877935
Mccarthy P.L.,,A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease,1996,Transplantation,41,10.1097/00007890-199609150-00015,United States;United States,Article,Buffalo;Houston,0,Journal,2-s2.0-9544224248
Drenth J.,,Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells,1996,Journal of Immunology,57,,United States;Netherlands;,Article,Cleveland;Nijmegen;,0,Journal,2-s2.0-0029951663
Dinarello C.A.,,Biologic basis for interleukin-1 in disease,1996,Blood,3523,10.1182/blood.v87.6.2095.bloodjournal8762095,United States;United States,Review,Medford;Denver,1,Journal,2-s2.0-0029979369
Drevlow B.,,Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis,1996,Arthritis and Rheumatism,79,10.1002/art.1780390212,United States,Article,Evanston,0,Journal,2-s2.0-0030039524
Ogilvie A.,,"IL-1β does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer",1996,Journal of Immunology,41,,Netherlands,Article,Amsterdam,0,Journal,2-s2.0-0029671325
Kaplanski G.,,Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism,1994,Blood,152,10.1182/blood.v84.12.4242.bloodjournal84124242,,Article,,1,Journal,2-s2.0-0027985033
Abraham E.,,Effects of therapy with interleukin-1 receptor antagonist on pulmonary cytokine expression following hemorrhage and resuscitation,1994,Lymphokine and Cytokine Research,9,,United States,Article,Denver,0,Journal,2-s2.0-0028596083
Antin J.H.,,Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease,1994,Blood,123,10.1182/blood.v84.4.1342.bloodjournal8441342,United States,Article,Boston,1,Journal,2-s2.0-0028086480
Fisher C.J.,,"Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial",1994,JAMA: The Journal of the American Medical Association,887,10.1001/jama.1994.03510470040032,United States,Article,Cleveland,0,Journal,2-s2.0-0028239555
Fisher C.,,"Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.",1994,Critical care medicine,392,10.1097/00003246-199401000-00008,United States,Article,Cleveland,0,Journal,2-s2.0-0028018567
Granowitz E.,,"Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans",1992,Cytokine,186,10.1016/1043-4666(92)90078-6,United States;United States;United States,Article,Boston;Thousand Oaks;Boston,0,Journal,2-s2.0-0026928357
Colotta F.,,Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products,1992,Blood,948,10.1182/blood.v80.8.2012.2012,Italy,Article,Milan,1,Journal,2-s2.0-0026795415
Dinarello C.,,Interleukin-1 and its relevance in patients treated with hemodialysis,1988,Kidney International,58,,United States,Article,Boston,0,Journal,2-s2.0-0023973493
Dinarello C.,,Interleukin 1 induces interleukin 1: I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro,1987,Journal of Immunology,380,,United States,Article,Boston,0,Journal,2-s2.0-0023201153
Dewhirst F.,,Purification and partial sequence of human osteoclast-activating factor: Identity with interleukin 1β,1985,Journal of Immunology,379,,United States,Article,Boston,0,Journal,2-s2.0-0022353748
Cannon J.,,Increased plasma interleukin-1 activity in women after ovulation,1985,Science,276,10.1126/science.3871966,United States,Article,Medford,0,Journal,2-s2.0-0021958529
Kurt-Jones E.,,Identification of a membrane-associated interleukin 1 in macrophages,1985,Proceedings of the National Academy of Sciences of the United States of America,362,10.1073/pnas.82.4.1204,United States,Article,Boston,1,Journal,2-s2.0-0343474749
